Chemotherapy-Induced Sclerosing Cholangitis Caused by Systemic Chemotherapy

A 61-year-old woman diagnosed with cervical cancer received systemic chemotherapy using paclitaxel and bevacizumab. Marked elevation of liver enzyme levels was observed. Ultrasonography and computed tomography showed wall thickening of the extrahepatic and intrahepatic bile ducts accompanied by stri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusakabe, Akira, Ohkawa, Kazuyoshi, Fukutake, Nobuyasu, Sakakibara, Mitsuru, Imai, Toshihiro, Abe, Yutaro, Takada, Ryoji, Ikezawa, Kenji, Nawa, Takatoshi, Ashida, Reiko, Kimura, Toshihiro, Nagata, Shigenori, Katayama, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722363/
https://www.ncbi.nlm.nih.gov/pubmed/31620533
http://dx.doi.org/10.14309/crj.0000000000000136
Descripción
Sumario:A 61-year-old woman diagnosed with cervical cancer received systemic chemotherapy using paclitaxel and bevacizumab. Marked elevation of liver enzyme levels was observed. Ultrasonography and computed tomography showed wall thickening of the extrahepatic and intrahepatic bile ducts accompanied by stricture and dilatation. According to these, she was diagnosed as chemotherapy-induced sclerosing cholangitis (CISC), a form of secondary sclerosing cholangitis. Although CISC triggered by systemic chemotherapy is rare, CISC should be considered as a clinically important adverse event of chemotherapy because it causes rapid deterioration of liver function and necessitates interruption of chemotherapy.

Ejemplares similares